In this setting, we hypothesized that HRQoL impairment in IBD patients may be related to their inflammation status (evaluating specific inflammation biomarkers (endocan, CRP, IL etc.)); this could be considered as a future study object. The gene discussed is CRP; the disease is inflammatory bowel disease.